Exceptional Ventures’ new healthtech fund targets prevention – and draws a line on AI: ‘Must be a human layer’
12 feb. 2026
12:50
UK-based Exceptional Ventures has reached the first close of its new £40m fund – with backing from major institutional investors.
We sat down with Anna Fortuny-Gomez, science lead at the firm, to talk about the new fund, the good and bad of AI in healthtech, and the story of a House of Lords member that discovered a tumour using an experimental AI-powered body scanner.
We sat down with Anna Fortuny-Gomez, science lead at the firm, to talk about the new fund, the good and bad of AI in healthtech, and the story of a House of Lords member that discovered a tumour using an experimental AI-powered body scanner.
Anna Fortuny-Gomez spent years in the lab developing drugs for cancer prevention and cardiovascular diseases before moving into venture capital. So it is perhaps no surprise that the PhD-wielding scientist is sceptical about the rise of tech fads such as biohacking, longevity, and even some AI tools.
“We see it as part of our bigger responsibility as investors to help separate the science from the fiction,” Fortuny-Gomez, Head of Platform, Science and Reputation at Exceptional Ventures, told Impact Loop in an interview.